Nafuredin A
Nafuredin A is a trinorsesquiterpene and polyketide derivative found in the mangrove sediment-derived fungi Talaromyces sp. SCSIO 41412 and Trichoderma harzianum D13. Nafuredin A regulates the ferroptosis pathway and upregulates ferroptosis-related genes. Nafuredin A alleviates hypoxia-reoxygenation-induced injury in oxygen-glucose deprivation/reperfusion cell models. Nafuredin A reduces pro-inflammatory cytokines and exerts hepatoprotective effects in animal models of hepatic ischemia-reperfusion injury. Nafuredin A inhibits the growth of phytopathogenic fungi Magnaporthe oryzae and Valsa mali. Nafuredin A can be used in studies related to hepatic ischemia-reperfusion injury and phytopathogenic fungal infections.
For research use only. We do not sell to patients.
- CAS No.: 224427-79-6
- Formula: C22H32O4
- Molecular Weight:360.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human A549 cells by SRB method
Cytotoxicity against human A549 cells by SRB method
|
[PMID: 29144133] |
| HCT-116 | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human HCT116 cells by SRB method
Cytotoxicity against human HCT116 cells by SRB method
|
[PMID: 29144133] |
| HeLa | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human HeLa cells by SRB method
Cytotoxicity against human HeLa cells by SRB method
|
[PMID: 29144133] |
| HL-60 | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human HL60 cells by MTT method
Cytotoxicity against human HL60 cells by MTT method
|
[PMID: 29144133] |
| K562 | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human K562 cells by MTT method
Cytotoxicity against human K562 cells by MTT method
|
[PMID: 29144133] |
| MCF7 | IC50 |
50 μM
Compound: 5
|
Cytotoxicity against human MCF7 cells by SRB method
Cytotoxicity against human MCF7 cells by SRB method
|
[PMID: 29144133] |
In Vitro
Nafuredin A (compound 3) (200-400 µM; 24 h) exhibits extremely low cytotoxicity against HepG2 cells at 200 µM, with an IC50 value of 303.6 µM[1].
Nafuredin A (200 µM; 24 h) enriches the ferroptosis pathway and upregulates ferroptosis-related genes NRF2, SLC7A11, FTH1, HMOX1, GCLC and GCLM when applied to HepG2 cells[1].
Nafuredin A (2.5-10 µM; 24 h pre-incubation) significantly reduces OGD/R-induced cytotoxicity in AML12 cells in a concentration-dependent manner[1].
Nafuredin A (compound 2) inhibits the growth of Magnaporthe oryzae with an MIC of 17.4 μM, inhibits Valsa mali with an MIC of 16.7 μM, and shows no activity against Pestallozzia theae[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:200, 267, 300, 333, 367, 400 µM
-
Incubation Time:24 h
-
Result:Showed minimal toxicity to HepG2 cells at 200 µM.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:100 µM
-
Incubation Time:24 h
-
Result:Robustly upregulated core ferroptosis regulatory genes: NRF2, SLC7A11, FTH1, HMOX1, GCLC, and GCLM.
-
Cell Line:mouse hepatocyte AML12 cells
-
Concentration:2.5, 5, 10 µM
-
Incubation Time:24 h (pre-incubation)
-
Result:Significantly attenuated OGD/R-induced cytotoxicity in a concentration-dependent manner.
Restored cellular viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, 20-23 g, hepatic ischemia-reperfusion injury model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; daily; 3 days
-
Result:Lowered serum ALT and AST levels by no less than 45% versus untreated groups.
Cut serum IL-1β content and hepatic IL-1β/IL-18 mRNA expression prominently.
Alleviated HIRI-triggered liver injury via relieving nuclear pyknosis, recovering sinusoidal endothelial integrity and rearranging hepatic cords.
Chemical Information
-
CAS No. 224427-79-6
-
Molecular Weight 360.49
-
Formula C22H32O4
-
SMILES
C[C@@]12[C@@]([C@H](C(O[C@@H]2/C=C/C=C/[C@H](C)C/C(C)=C/C=C/[C@@H](C)CC)=O)O)([H])O1
-
Structure Classification
-
Initial Source
Talaromyces aculeatus and amangrove-derived fungus Penicillium variabile
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)